Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Bevacizumab (Avastin) on Pterygium

This study has been completed.
Information provided by (Responsible Party):
University of Alabama at Birmingham Identifier:
First received: December 26, 2007
Last updated: May 20, 2014
Last verified: May 2012
The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.

Condition Intervention Phase
Drug: local injection of bevacizumab
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Effect of Bevacizumab (Avastin) on Pterygium

Resource links provided by NLM:

Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. [ Time Frame: Baseline and 3 months ]

    Growth of the pterygium was defined as an increase in the area of the pterygium as measured from the limbus toward the visual axis. This would be a positive change value indicating progression

    Regression of the pterygium was defined as a decrease in the area of the pterygium length measured from the limbus toward the visual axis. This would be negative change value indicating regression.

Secondary Outcome Measures:
  • Number of Patients Having Surgical Removal of Pterygium. [ Time Frame: 12 months ]
    The number of patients having surgical removal of pterygium within 12 months.

Enrollment: 5
Study Start Date: August 2007
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bevacizumab
Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline
Drug: local injection of bevacizumab
Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 19 years of age and older
  • Diagnosis of pterygia
  • healthy enough to make scheduled follow-up visits

Exclusion Criteria:

  • Women of childbearing potential and males who plan to father a child during their participation in the study will be excluded from the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00592176

United States, Alabama
Callahan Eye Foundation Hospital
Birmingham, Alabama, United States, 35233
Sponsors and Collaborators
University of Alabama at Birmingham
Principal Investigator: Tyler A Hall, MD University of Alabama at Birmingham
  More Information

Responsible Party: University of Alabama at Birmingham Identifier: NCT00592176     History of Changes
Other Study ID Numbers: F070323011
Study First Received: December 26, 2007
Results First Received: May 21, 2012
Last Updated: May 20, 2014

Additional relevant MeSH terms:
Conjunctival Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on May 25, 2017